Txcell

Txcell: A Revolutionary Biotechnology Company

Txcell is a biotechnology company that has been at the forefront of developing innovative therapies for various diseases. The company was founded in 2001 and has since then been dedicated to improving the lives of patients suffering from severe chronic inflammatory and autoimmune diseases.

In November 2018, Txcell became a part of Sangamo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing genomic medicines to transform the lives of patients with serious diseases. This acquisition has enabled Txcell to leverage Sangamo's expertise in gene editing and cell therapy, thereby expanding its capabilities in developing novel treatments for various disorders.

Txcell's Approach

Txcell's approach is based on using regulatory T cells (Tregs) as therapeutic agents. Tregs are specialized immune cells that play a crucial role in maintaining immune homeostasis by suppressing excessive immune responses. In autoimmune and inflammatory diseases, there is an imbalance between pro-inflammatory and anti-inflammatory responses, leading to tissue damage and disease progression.

Txcell's technology involves isolating Tregs from patient blood samples, expanding them ex vivo (outside the body), modifying them if necessary using gene editing techniques such as CRISPR/Cas9 or zinc finger nucleases (ZFNs), and re-infusing them back into the patient. This approach aims to restore immune balance by increasing the number of functional Tregs that can suppress harmful immune responses.

Txcell's Pipeline

Txcell has several programs in its pipeline targeting different indications:

Ovasave®: Ovasave® is Txcell's lead product candidate for treating Crohn’s disease, an inflammatory bowel disease characterized by chronic inflammation of the digestive tract. Ovasave® consists of autologous antigen-specific Tregs directed against ovalbumin (a protein found in egg whites). The rationale behind this approach is that ovalbumin may act as a surrogate antigen for other antigens that are involved in the pathogenesis of Crohn's disease. Ovasave® has completed a phase IIb clinical trial, which showed promising results in terms of safety and efficacy.

Col-Treg: Col-Treg is Txcell's program for treating autoimmune uveitis, an inflammatory eye disease that can lead to blindness if left untreated. Col-Treg consists of autologous Tregs directed against collagen type II (a protein found in the cartilage). The rationale behind this approach is that collagen type II may act as a surrogate antigen for other antigens that are involved in the pathogenesis of autoimmune uveitis. Col-Treg is currently in preclinical development.

Tx200: Tx200 is Txcell's program for treating refractory lupus nephritis, a severe form of systemic lupus erythematosus (SLE) characterized by inflammation and damage to the kidneys. Tx200 consists of autologous polyclonal Tregs expanded ex vivo using a proprietary process. The rationale behind this approach is to increase the number of functional Tregs that can suppress harmful immune responses in SLE patients. Tx200 is currently in preclinical development.

Txcell's Competitive Advantage

Txcell's technology has several advantages over traditional approaches:

Specificity: By using antigen-specific Tregs, Txcell can target only those immune cells that are responsible for causing disease while sparing healthy cells.

Safety: Since Tregs have a natural ability to suppress immune responses, they have an excellent safety profile compared to other immunosuppressive drugs used in autoimmune and inflammatory diseases.

Efficacy: By restoring immune balance, Txcell's approach aims to provide long-lasting benefits with minimal side effects compared to conventional therapies.

Conclusion

Txcell has been at the forefront of developing innovative therapies based on regulatory T cells for various diseases. With its acquisition by Sangamo Therapeutics, Inc., it has expanded its capabilities and expertise in gene editing and cell therapy. Txcell's technology has several advantages over traditional approaches, including specificity, safety, and efficacy. With its promising pipeline of products targeting different indications, Txcell is poised to revolutionize the treatment of autoimmune and inflammatory diseases.